#United States #New York #Securities Class Action #PROCEPT BioRobotics #SueWallSt

SueWallSt Warns Investors of Class Action Deadline

Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) are urged by SueWallSt to pay attention to an important deadline related to a securities class action. This legal action was initiated due to allegations of misleading statements and a lack of sufficient disclosures regarding the company's operations and financial health.

Background of the Case

The securities class action was formally filed on behalf of shareholders who bought PROCEPT securities between February 28, 2024, and February 25, 2026. During this period, the share prices drastically declined. Initially, the stock traded around $100 before plummeting to below $25 after disclosures regarding handpiece sales and field inventory issues came to light.

The crux of the allegations revolves around whether PROCEPT adequately disclosed risks related to an undisclosed discount program that led customers to purchase more handpieces than necessary, creating an artificial surge in sales metrics. This could mislead investors and suggest unsustainable demand when, in reality, the company’s future earnings potential was poised to suffer.

Key Allegations

The class action claims that PROCEPT did not properly reveal information about how handpiece sales had outpaced actual procedure demands throughout several quarters. In fact, it is alleged that customers had amassed over 10,000 excess handpieces by the end of the relevant period.

Moreover, plaintiffs assert that the reported metrics on recurring revenue were inflated due to these bulk purchases, rather than originating from genuine sales driven by patient procedures. They argue that vital data was withheld, making it difficult for investors to gauge the ongoing viability of the company's primary products accurately.

Concerns Raised by Investors

Specific issues raised in the lawsuit include:

• - Insufficient risk disclosures, which failed to alert investors to the impending financial fallout from inventory overstock.
• - Inadequate public communications regarding operational setbacks, such as salinity shortages, which were inaccurately portrayed as temporary disruptions.
• - A lack of transparency concerning the sustainability of handpiece sales, essential for evaluating PROCEPT’s market value.

Joseph E. Levi, the attorney representing the plaintiffs, emphasized that generic language regarding risks does not suffice if the company has specific operational problems that are already negatively impacting performance. He stated that PROCEPT's public filings did not provide a fair representation of the demand for handpieces prior to the significant drop in stock price.

What Investors Should Do

Investors who purchased shares during the specified class period and experienced losses may be eligible for compensation. Key dates to note include the September 22, 2026, deadline for lead plaintiff applications. Those interested in participating can submit their information using the specific procedures laid out by SueWallSt.

For investors who sold their PRCT shares, the eligibility to join the class action does not rely on current ownership, meaning losses incurred can still be compensated as long as purchase dates fall within the class period.

Conclusion

As the September deadline approaches, potential claimants should act swiftly to determine their eligibility. Investors need to be diligent in seeking comprehensive legal guidance to navigate this complex situation and potentially recover their losses.

SueWallSt, supported by the legal expertise of Levi Korsinsky LLP, remains committed to advocating for shareholders affected by securities fraud. With a proven history of securing substantial settlements for investors, they offer a vital resource for those impacted by the alleged discrepancies associated with PROCEPT BioRobotics Corporation.